Cite
HARVARD Citation
Dimopoulos, M. et al. (2018). Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply. Lancet oncology. 19 (1), pp. e2-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dimopoulos, M. et al. (2018). Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply. Lancet oncology. 19 (1), pp. e2-. [Online].